The blood-brain barrier (BBB)-shielding function provided by endothelial cells is important in the treatment of neurological diseases, because this exclusion of foreign substances also restricts the entry of many potentially therapeutic agents into the brain. Recently, potential applications of iron chelators e.g. Deferiprone, Deferasirox, Desferrioxamine and others for clinical management of neuodegenerative diseases have attracted attention. Since these chelators have limited ability to cross the BBB on their own, several peptides e.g. TAT-peptide and penetratin, which have the potential to cross BBB, can be used as delivery vectors for these chelators. These peptides will be synthesized following solid state peptide synthesis techniques, and will be conjugated to the iron chelators. Fe-binding ability of the conjugates, their ability to decrease plasmatic or cytossolic pools of labile iron, and also the comparative effects of externally added pro-oxidants (such as H2O2) on Fe-catalysed generation of reactive species upon binding with the new chelators will be assessed.
News published in Agência FAPESP Newsletter about the scholarship: